While Celldex Therapeutics Inc has underperformed by -2.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLDX rose by 5.07%, with highs and lows ranging from $30.41 to $14.40, whereas the simple moving average jumped by 20.68% in the last 200 days.
On October 13, 2025, Barclays started tracking Celldex Therapeutics Inc (NASDAQ: CLDX) recommending Underweight. A report published by Canaccord Genuity on April 28, 2025, Initiated its previous ‘Buy’ rating for CLDX. Morgan Stanley also rated CLDX shares as ‘Overweight’, setting a target price of $46 on the company’s shares in an initiating report dated March 20, 2025. UBS Initiated an Buy rating on February 13, 2025, and assigned a price target of $44. Citigroup initiated its ‘Buy’ rating for CLDX, as published in its report on October 07, 2024. Goldman’s report from September 30, 2024 suggests a price prediction of $45 for CLDX shares, giving the stock a ‘Neutral’ rating. Wolfe Research also rated the stock as ‘Peer Perform’.
Analysis of Celldex Therapeutics Inc (CLDX)
Further, the quarter-over-quarter decrease in sales is -70.78%, showing a negative trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Celldex Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -27.17% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.67, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and CLDX is recording an average volume of 1.23M. On a monthly basis, the volatility of the stock is set at 4.80%, whereas on a weekly basis, it is put at 6.76%, with a loss of -3.59% over the past seven days. Furthermore, long-term investors anticipate a median target price of $53.85, showing growth from the present price of $26.55, which can serve as yet another indication of whether CLDX is worth investing in or should be passed over.
How Do You Analyze Celldex Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.84%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 108.78% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
